EuroAPI grows in oligos
EuroAPI has agreed to acquire BianoGMP, a CDMO focused on small-scale, early-stage oligonucleotides, for about €10 million. The deal is expected to close in Q4. Created in 2017 by Professor Tobias Pöhlmann and Dr Rolf Günther, Biano is based in Gera, Germany, with a client base in Europe and Asia.
EuroAPI said that this will strengthen its market position in oligonucleotides “by adding to its current offer a reputable oligonucleotide CDMO pure player, with capacity to grow”. Biano will complement the expansion of its own oligonucleotide capacity, thus enabling it to offer larger-scale projects.
Oligonucleotides are a priority segment for EuroAPI’s CDMO business. Last year it announced an initial investment of €18 million in new manufacturing equipment to increase peptide and oligonucleotide capacity at its Frankfurt site to about 500 kg/year by 2025. It is currently working on 18 large molecule projects, including peptides, oligonucleotides and lipids, among a total of 79